Drugs / ABF-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07330674 | Feb 2026 → Nov 2027 expected | age-related macular degeneration | Aptabio Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABF-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07330674 ↗ |
| Route | Oral | “Capsule, once daily by mouth” NCT07330674 ↗ |